Key Takeaways Protein shortfalls are easier to miss on GLP-1: Smaller portions and reduced appetite can lower protein intake without it being obvious, even when meals feel sufficient
These medications were designed to treat type 2 diabetes but have increasingly been prescribed for off-label weight loss
These medications are typically considered when metformin and other treatments haven't achieved adequate glycaemic control, and are usually prescribed within a specific therapy sequence
In seven large cardiovascular studies, all agents shown at least non-inferiority, with liraglutide, subcutaneous semaglutide, and dulaglutide revealing statistically significant decreases in cardiovascular outcomes (Sheahan et al
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying
There are currently three FDA-approved semaglutide products: Ozempic injection and Rybelsus tablets are approved to lower blood sugar levels in adults with type 2 diabetes mellitus, in addition to diet and exercise
,aspect=fit)
